Conferences
ASCO GU 2023: 318: Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA
February 16, 2023
ASCO GU 2023: Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer
February 16, 2023
ASCO GU 2023: Machine-Learning to Predict Utility of Circulating Tumor DNA (ctDNA) for Somatic Genotyping
February 16, 2023
ASCO GU 2023: Best of the Journals: Prostate Cancer - Medical Oncology
February 16, 2023
ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic Hormone-Sensitive Prostate Cancer: Open-Label Single-Arm Study with an External Control Arm (ARASEC)
February 16, 2023
ASCO GU 2023: Time Interval Between Radium‑223 Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study
February 16, 2023
ASCO GU 2023: Initial Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone
February 16, 2023
ASCO GU 2023: Evaluation of a Novel Transcriptomic Tumor Signature (PROSTest) as Response Biomarker for 177Lu-PSMA Therapy in Advanced Prostate Cancer
February 16, 2023
ASCO GU 2023: Best of the Journals: Prostate Cancer - Urologic Oncology
February 16, 2023